BD PharmingenTM FITC Mouse IgG1, kappa Isotype Control

Description

Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. No. P-8139 and calcium ionophone A23187 250 ng/ml final concentration; Sigma, Cat. No. C-9275 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were stained with PE-Cy5 formerly referred to as BD-Cy-Chrome - anti-CD3 Cy-Chrome - UCHT1, Cat. No. 555334 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC-mouse anti-human IFN-gamma antibody FITC-4S.B3, Cat. No. 554551; left panel or FITC-MOPC-21 immunoglobulin 0.25 mug; Cat. No. 554679; right panel by using the BD Bioscience staining protocol. To demonstrate specificity of staining, the binding of FITC-4S.B3 was blocked by preincubation of fixed/permeabilized cells with excess unlabelled 4S.B3 antibody 5 mug; Cat. No. 554549 . The quadrant markers for the bivariate dot plot were set based on autofluorescence controls and verified using the unlabelled 4S.B3 antibody blocking control. Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. No. P-8139 and calcium ionophone A23187 250 ng/ml final concentration; Sigma, Cat. No. C-9275 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were stained with PE-Cy5 formerly referred to as BD-Cy-Chrome - anti-CD3 Cy-Chrome - UCHT1, Cat. No. 555334 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC-mouse anti-human IFN-gamma antibody FITC-4S.B3, Cat. No. 554551; left panel or FITC-MOPC-21 immunoglobulin 0.25 mug; Cat. No. 554679; right panel by using the BD Bioscience staining protocol. To demonstrate specificity of staining, the binding of FITC-4S.B3 was blocked by preincubation of fixed/permeabilized cells with excess unlabelled 4S.B3 antibody 5 mug; Cat. No. 554549 . The quadrant markers for the bivariate dot plot were set based on autofluorescence controls and verified using the unlabelled 4S.B3 antibody blocking control. Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. No. P-8139 and calcium ionophone A23187 250 ng/ml final concentration; Sigma, Cat. No. C-9275 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were stained with PE-Cy5 formerly referred to as BD-Cy-Chrome - anti-CD3 Cy-Chrome - UCHT1, Cat. No. 555334 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC-mouse anti-human IFN-gamma antibody FITC-4S.B3, Cat. No. 554551; left panel or FITC-MOPC-21 immunoglobulin 0.25 mug; Cat. No. 554679; right panel by using the BD Bioscience staining protocol. To demonstrate specificity of staining, the binding of FITC-4S.B3 was blocked by preincubation of fixed/permeabilized cells with excess unlabelled 4S.B3 antibody 5 mug; Cat. No. 554549 . The quadrant markers for the bivariate dot plot were set based on autofluorescence controls and verified using the unlabelled 4S.B3 antibody blocking control. Show More Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. No. P-8139 and calcium ionophone A23187 250 ng/ml final concentration; Sigma, Cat. No. C-9275 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were stained with PE-Cy5 formerly referred to as BD-Cy-Chrome - anti-CD3 Cy-Chrome - UCHT1, Cat. No. 555334 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC-mouse anti-human IFN-gamma antibody FITC-4S.B3, Cat. No. 554551; left panel or FITC-MOPC-21 immunoglobulin 0.25 mug; Cat. No. 554679; right panel by using the BD Bioscience staining protocol. To demonstrate specificity of staining, the binding of FITC-4S.B3 was blocked by preincubation of fixed/permeabilized cells with excess unlabelled 4S.B3 antibody 5 mug; Cat. No. 554549 . The quadrant markers for the bivariate dot plot were set based on autofluorescence controls and verified using the unlabelled 4S.B3 antibody blocking control. Show More Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. No. P-8139 and calcium ionophone A23187 250 ng/ml final concentration; Sigma, Cat. No. C-9275 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were stained with PE-Cy5 formerly referred to as BD-Cy-Chrome - anti-CD3 Cy-Chrome - UCHT1, Cat. No. 555334 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC-mouse anti-human IFN-gamma antibody FITC-4S.B3, Cat. No. 554551; left panel or FITC-MOPC-21 immunoglobulin 0.25 mug; Cat. No. 554679; right panel by using the BD Bioscience staining protocol. To demonstrate specificity of staining, the binding of FITC-4S.B3 was blocked by preincubation of fixed/permeabilized cells with excess unlabelled 4S.B3 antibody 5 mug; Cat. No. 554549 . The quadrant markers for the bivariate dot plot were set based on autofluorescence controls and verified using the unlabelled 4S.B3 antibody blocking control. Expression of IFN-gamma by stimulated human peripheral blood mononuclear cells PBMC . Human PBMC were stimulated for 6 hours with PMA 50 ng/ml final concentration; Sigma, Cat. No. P-8139 and calcium ionophone A23187 250 ng/ml final concentration; Sigma, Cat. No. C-9275 in the presence of GolgiStop 2 muM final concentration; Cat. No. 554724 . The PBMC were stained with PE-Cy5 formerly referred to as BD-Cy-Chrome - anti-CD3 Cy-Chrome - UCHT1, Cat. No. 555334 , fixed, permeabilized, and subsequently stained with 0.25 mug of FITC-mouse anti-human IFN-gamma antibody FITC-4S.B3, Cat. No. 554551; left panel or FITC-MOPC-21 immunoglobulin 0.25 mug; Cat. No. 554679; right panel by using the BD Bioscience staining protocol. To demonstrate specificity of staining, the binding of FITC-4S.B3 was blocked by preincubation of fixed/permeabilized cells with excess unlabelled 4S.B3 antibody 5 mug; Cat. No. 554549 . The quadrant markers for the bivariate dot plot were set based on autofluorescence controls and verified using the unlabelled 4S.B3 antibody blocking control.